France’s Sanofi SA expected to begin at least ten phase 3 studies over the next 12 months.

Among the studies the French pharma company will bring forward there will be evaluations of new treatments for chronic obstructive pulmonary disease and eosinophilic esophagitis, for autosomal dominant polycystic kidney disease and for type 2 diabetes. Also in the next year it will file for regulation two investigational cancer drugs–cemiplimab and isatuximab–a novel therapy for type 1 diabetes called sotagliflozin and a potential treatment for uncontrolled, persistent asthma called dupilumab.

In total, the company’s pipeline includes 71 research-and-development projects, 37 of which are new molecular entities and novel vaccines.

Source: Fox Business